SI
SI-BONE, Inc.
SIBN · NASDAQ
$18.70 +0.86% (+$0.16)
1M +0.05%
Market Cap $829.3M
P/E Ratio -
Div. Yield -
ROE 8.23%
Bulios Fair Price
$11.76
37.1% downside
Current Price
$18.7
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SIBN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
45 /100
Fair P/B 4.55x
P/S 3.88x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 21.78%
Rev. growth 23.60%
FCF growth N/A
Profitability
20 /100
Weak Net margin 6.85%
Op. margin 8.31%
FCF margin 2.05%
Quality
11 /100
Poor ROE 8.23%
ROA 5.88%
Asset turnover 0.86x
Debt
69 /100
Low Current ratio 9.15x
Int. coverage -5.41x
Debt/Equity 0.04x
Stability
86 /100
Stable Rev. volatility 5.91%
EPS volatility 3.87%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SIBN
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Laura A. Francis
Employees
376
Headquarters
Santa Clara
Upcoming events
09 NOV
Earnings
Upcoming earnings report